UK agency says Pfizer breast cancer drug too expensive

LONDON (Reuters) - Pfizer's breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain's state-run health service, the country's healthcare cost-effectiveness watchdog said on Friday.

The National Institute for Health and Care Excellence (NICE) said in draft guidance that although the medicine was likely to offer some improvement in overall survival, this could not be quantified from clinical trials.

"Even when allowing for these potential benefits, it was still not enough to make palbociclib cost effective at its current price," Carole Longson, director of NICE's center for health technology assessment, said in a statement on Friday.

Ibrance's list price is 2,950 pounds ($3,700) per 28 days.

Pfizer UK's oncology head David Montgomery noted that the NICE decision was not final decision and said the U.S. drugmaker was committed to working to try and find a solution to make the drug available.

(Reporting by Ben Hirschler, editing by Pritha Sarkar)

Must Read

Home Depot rides housing boom to record sales, profit

Aug 16, 2016

Home Depot posted record sales and earnings during its second quarter and raised its profit expectations for the year as housing market continues to warm up

Are France's burkini bans sexist, or liberating?

Aug 17, 2016

Male officials are dictating what women can wear on French beaches _ and people across a wide swath of French society say that's a good thing

Asian stocks climb on signs US rate hike off table for now

Aug 18, 2016

Asian stocks rose Wednesday after Wall Street edged higher on news the U.S. Federal Reserve is in no hurry to raise interest rates


Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: